Acinar prostate adenocarcinoma, foamy gland variant

Summary

Acinar prostate adenocarcinoma, foamy gland variant (MONDO:0006066) is a disease. A subtype of prostatic acinar adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acinar prostate adenocarcinoma, foamy gland variant
Mondo ID	MONDO:0006066
EFO	EFO:1000064
NCIT	C39882
UMLS	C5787290
MedGen	1835068
GARD	0027738
Is cancer (heuristic)	no

Disease family

This is a subtype of prostatic acinar adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › acinar cell carcinoma › prostatic acinar adenocarcinoma › acinar prostate adenocarcinoma, foamy gland variant

Related subtypes (3): acinar prostate adenocarcinoma, signet ring variant, lymphoepithelioma-like acinar prostate adenocarcinoma, acinar prostate mucinous adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.